Goodrx Shares Surge 37.27% on $270M Volume Jumps 4360% to Rank 346th Partners with Novo Nordisk for $499 Month GLP1 Pricing

Goodrx (GDRX) surged 37.27% on August 18, 2025, with a trading volume of $270 million, a 4,360% increase from the prior day, ranking 346th in market activity. The rally followed the company’s announcement of a partnership with Novo Nordisk to sell Ozempic and Wegovy at a fixed cash price of $499 per month for eligible self-paying customers. This marks the first time Goodrx offers a cash price for GLP-1 medications, addressing demand from 17 million users who sought GLP-1 savings on its platform in the past year.

The collaboration aligns with Novo Nordisk’s broader efforts to counter competition in the GLP-1 market, particularly against compounded versions of its drugs. Goodrx CEO Wendy Barnes emphasized the company’s commitment to FDA-approved pathways, differentiating from telehealth providers like Hims & Hers, which faced legal disputes with Novo Nordisk over compounded alternatives. Barnes stated Goodrx would not support non-FDA-approved drugs, citing patient safety and legal clarity.

Novo Nordisk’s recent legal actions against compounded GLP-1 sellers highlight the sector’s regulatory challenges. The company has filed over 130 lawsuits nationwide, arguing that these alternatives infringe on intellectual property rights and pose safety risks. Goodrx’s partnership, however, leverages its pharmacy network to provide accessible pricing without relying on compounded formulations, positioning it as a key player in the $100+ billion GLP-1 market.

Backtest results for GDRX’s performance following a 30% intraday surge show mixed short-term outcomes. The 3-day win rate was 48.95%, the 10-day win rate 50.48%, and the 30-day win rate 47.23%, with a maximum return of -0.09% over 30 days. This suggests volatility persists despite the partnership’s immediate market impact.